Staar Surgical AI Stock Analysis
Want to see STAA full AI Analyst Report?
Staar Surgical (STAA) AI Stock Analysis
Staar Surgical
(NASDAQ:STAA)
The score is held back mainly by weakened and volatile profitability/cash-flow history (despite a strong, low-leverage balance sheet) and an extremely high P/E with no dividend support. Offsetting factors include constructive technical momentum and a positive earnings-call tone highlighting improving margins, cost discipline, and pipeline progress, though supply constraints and limited forward guidance remain meaningful near-term risks.
Staar Surgical Key Performance Indicators (KPIs)
Revenue by GeographyBreaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Foreign sales overwhelmingly drive Staar’s top line but are highly lumpy—big quarter-to-quarter swings point to timing of large international orders or distributor restocking rather than steady end-market demand. Domestic revenue is small but steadily creeping higher, signaling limited U.S. penetration and low diversification benefit. For investors this means headline revenue and margins will be volatile until management smooths international channel timing or grows domestic share; focus on order backlog, distributor contracts and reimbursement/approval updates for true momentum clarity.
Staar Surgical (STAA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.28B
- Dividend Yield
- ―
- Average Volume (3M)
- 850.67K
- Price to Earnings (P/E)
- 2542.4
- Beta (1Y)
- 1.05
- Revenue Growth
- 42.36%
- EPS Growth
- ―
- Country
- US
- Employees
- 921
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Staar Surgical Business Overview & Revenue Model
Company Description
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated del...
How the Company Makes Money
STAAR Surgical makes money primarily by selling implantable lenses and related ophthalmic products to eye-care customers through a combination of direct sales and distribution partners, depending on the geography. The company’s principal revenue stre...
Staar Surgical Earnings Call Summary
The call was broadly positive. Management reported record nine-month revenue, strong cash generation, GAAP profitability, growth across China and most international regions, expanding EVO+ and toric adoption, new manufacturing capacity, and progress toward presbyopia trials. The main negatives were lower reported third-quarter revenue and profitability versus the prior-year comparison, reduced gross margin from stated temporary pressures, supply constraints, regional weakness in Japan and South Korea, and limited forward guidance. Highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management expects fourth quarter gross margin to be above the third quarter and gross margin to continue to improve in 2027, remains on track to meet the $225 million adjusted operating expense target, and expects strong full year GAAP net income and free cash flow; in China, Q4 would be lower from a shape of demand standpoint, yet the company expects to grow versus last year, while stopping short of giving guidance or saying when it might be willing to give guidance for 2027. Each percentage point of yield improvement could generate approximately $750,000 to $1 million in annual incremental gross profit, and first-in-human trials for 2 Collamer-based presbyopia products are expected to begin patient enrollment in the next few months, subject to the receipt of the remaining required regulatory authorizations.
Staar Surgical Financial Statement Overview
Summary
Financials are mixed. The balance sheet is a clear strength with low leverage (debt-to-equity ~0.09) and ample flexibility (Balance Sheet Score 76). However, profitability has deteriorated versus prior years with multi-year losses and only near break-even TTM results (Income Statement Score 44). Cash flow is improving in TTM (positive operating and free cash flow), but remains volatile across years (Cash Flow Score 52).
Income Statement
44NeutralBalance Sheet
76PositiveCash Flow
52Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 328.27M | 239.44M | 313.90M | 322.42M | 284.39M | 230.47M |
| Gross Profit | 240.13M | 182.42M | 239.58M | 252.65M | 223.38M | 178.64M |
| EBITDA | 17.02M | -73.94M | -2.16M | 38.82M | 50.06M | 34.98M |
| Net Income | 530.00K | -80.45M | -20.21M | 21.35M | 39.66M | 27.51M |
Balance Sheet | ||||||
| Total Assets | 485.16M | 451.68M | 509.52M | 488.69M | 418.82M | 345.78M |
| Cash, Cash Equivalents and Short-Term Investments | 206.41M | 187.54M | 230.49M | 220.73M | 211.64M | 199.71M |
| Total Debt | 33.64M | 38.35M | 38.74M | 35.83M | 31.04M | 32.06M |
| Total Liabilities | 109.03M | 107.49M | 112.19M | 102.74M | 82.71M | 87.22M |
| Stockholders Equity | 376.13M | 344.18M | 397.33M | 385.95M | 336.11M | 258.56M |
Cash Flow | ||||||
| Free Cash Flow | 17.85M | -40.05M | -7.67M | -3.59M | 17.61M | 30.32M |
| Operating Cash Flow | 21.40M | -34.23M | 15.72M | 14.59M | 35.72M | 43.96M |
| Investing Cash Flow | -59.30M | 46.34M | -59.22M | 74.35M | -156.38M | -13.64M |
| Financing Cash Flow | -4.56M | -4.55M | 5.72M | 7.42M | 8.30M | 17.79M |
Staar Surgical Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STAA, the sentiment is Positive. The current price of 25.56 is above the 20-day moving average (MA) of 24.88, above the 50-day MA of 23.05, and above the 200-day MA of 23.97, indicating a bullish trend. The MACD of 0.89 indicates Negative momentum. The RSI at 55.37 is Neutral, neither overbought nor oversold. The STOCH value of 43.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STAA.
Staar Surgical Risk Analysis
Staar Surgical disclosed 41 risk factors in its most recent earnings report. Staar Surgical reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksStaar Surgical Peers Comparison
Overall Rating
BLCO65Neutral
STAA58Neutral
COO57Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 65Neutral | $7.45B | -67.36 | -1.73% | ― | 8.88% | 63.73% | |
| 58Neutral | $1.28B | 2542.43 | 0.15% | ― | 42.36% | ― | |
| 57Neutral | $11.55B | 20.78 | 6.88% | ― | 4.73% | 43.89% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| STAA | Staar Surgical Company | 25.56 | -0.89 | -3.36% | |
| COO | Cooper Companies | 60.72 | -11.43 | -15.84% | |
| BLCO | Bausch + Lomb Corporation | 20.83 | 6.21 | 42.48% |
Staar Surgical Corporate Events
STAAR Surgical Reports Third-Quarter 2026 Financial Results
PositiveSTAAR Surgical reported third-quarter 2026 results for the period ended October 2, 2026, with net sales of $83.4 million, net income of $5.6 million and adjusted EBITDA of $14.4 million. For the first nine months, revenue reached a record $270.5 mill...
Staar Surgical Reappoints David Bailey to Drive Growth
PositiveOn September 8, 2026, STAAR Surgical appointed former Chief Executive Officer David Bailey as Chief Commercial Officer, returning him to the company’s executive committee with responsibility for driving revenue growth and commercial strategy. Bailey,...
Staar Surgical posts strong Q2 growth and profits
PositiveSTAAR Surgical reported strong financial performance for the second quarter ended July 3, 2026, highlighted by net sales of $93.5 million, up 111% year over year, and a swing to net income of $8.1 million from a loss a year earlier. Adjusted EBITDA r...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
